Harpreet Singh on Clinical Trial Eligibility in the Elderly Cancer Population
Harpreet Singh of the FDA discusses how clinical trial populations are not always reflective of the population of patients who eventually end up getting treated by the therapies.
Harpreet Singh of the FDA discusses how clinical trial populations are not always reflective of the population of patients who eventually end up getting treated by the therapies.
Clinical trials typically enroll patients who are under 65 years of age, though many patients with cancer are older. The FDA formed a group to look into the reasons for this discrepancy and found that strict eligibility criteria, for example, not allowing anyone with organ dysfunction to enroll, is a frequent reason that older patients are deemed ineligible for a trial.
Singh asks if these criteria are always necessary, especially when testing immunotherapies, which tend to have fewer toxicities and side effects.
Oncology Nurses Provide Patients an Avenue to Supportive Care
November 12th 2019Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
March 23rd 2016Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making
March 18th 2016Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).
